Allopathic corona vaccine update

Glenmark Pharmaceuticals (A pharmaceutical company located in Mumbai) has launched an anti-viral drug, FAVIPIRAVIR (Brand name- fabiflu) for treatment of mild to moderate Covid-19 patients.

Cipla and Hetero have also get approval from the Drug Controller General of India (DCGI) to launch REMDESIVIR (Brand name- cipremi and covifor)

Some statements from medical officials

Dr.Sanjay Rai (Professor at centre for community medicine, AIIMS (Delhi) said, "Till date, we don't have evidence that a particular drug is effective, so we cannot call any drug game changer till then. With their launch it will only be clear in the future how effective they will be. Whether they can play a supportive role in Covid-19 is also not yet known"

Also, Dr.Vikas Maurya (Director- Department of pulmonology, fortis hospital (Shalimar Bagh) said,

"Drugs like REMDESIVIR and FAVIPIRAVIR were no game changers as they were used for other diseases and now been found useful someway in treating Covid-19 patients"

He said, "It is a positive development as it is better to have something in hand than nothing" 

Drug firms Hetero and Cipla have received approval from DCGI to launch REMDESIVIR which will be available in 100 mg vials (injectable) and this will be given only under the supervision of health care practitioner. It's price will be in the range of (₹5000 - 6000) per dose.

Glenmark Pharmaceuticals' anti-viral drug FAVIPIRAVIR for the treatment of mild to moderate Covid-19 patients will be available in ₹103 per tablet.

The statements of some officials mentioned above are same as given by them to the Press Trust of India (PTI).